Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19655
Title: A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting.
Authors: Ameratunga, Malaka;Miller, Dorothea;Ng, Wayne;Wada, Morikatsu;Gonzalvo, Augusto;Cher, Lawrence M;Gan, Hui K
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
La Trobe University School of Cancer Medicine, Melbourne, Australia
Issue Date: Oct-2018
EDate: 2018-06-29
Citation: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2018; 56: 127-130
Abstract: Multi-disciplinary team meetings (MDTs) are considered essential to quality cancer care. For some malignancies, MDTs have been associated with improved outcomes, but data regarding the neuro-oncology MDT is limited. We prospectively described the MDT at our institution and evaluated its impact on clinical management. Cases were discussed amongst the treating team and a pre-MDT plan and reason for discussion (RFD) was documented before the MDT. Patient specific clinical data was captured prospectively, with further pathological and radiological information captured during the MDT. Subsequently, the MDT consensus decision was recorded. High impact decisions (HID) were those in which the pre-MDT plan was substantially modified. A HID rate of >10% was considered clinically significant. Adherence to MDT recommendations was recorded. Seventy-nine cases were discussed at the MDT. Fifty-two cases (66%) were male. The median age was 53 (17-84). Thirty-three cases were new diagnoses and the remainder were relapsed/progressive disease. Thirty-nine cases were primary brain tumours, 25 were metastatic tumours and 15 were other. Twenty-eight (35%) had HID. No RFDs were statistically significantly associated with a HID (p = 0.265). Adherence data was collected for 95% (75) of cases. Treatment concordance with the MDT plan occurred in 90% (67) of cases. For cases of non-concordance, six out of eight (75%) were due to patient choice. Overall, a clinically significant proportion of treatment modifications are made at the neuro-oncology MDT. There were no case types which did not benefit from MDT discussion. MDT recommendations were largely adhered to, and in cases of non-concordance, were largely due to patient choice.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19655
DOI: 10.1016/j.jocn.2018.06.032
PubMed URL: 30318071
Type: Journal Article
Subjects: Multidisciplinary team meeting
Neuro-oncology
Tumour board
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.